Abstract
Normal hematopoiesis is maintained by dynamic interactions between hematopoietic cells and the bone marrow microenvironment. In hematological malignancies, there are reciprocal interactions between leukemic cells and cells of the bone marrow microenvironment such as stroma, osteoblasts and endothelium. In this review, we will discuss the influence of the microenvironment on the evolution of the leukemic phenotype. We propose that specific niches within the bone marrow microenvironment may provide a sanctuary for subpopulations of leukemic cells to evade chemotherapyinduced death and allow acquisition of a drug-resistant phenotype. We will also discuss recent studies that suggest novel therapeutic interventions targeting the microenvironment/leukemia interaction. Focus on this stroma-leukemia crosstalk may result in the development of strategies that alleviate the acquisition of a chemoresistant phenotype and enhance the efficacy of therapies in hematological malignancies.
Keywords: Leukemia, microenvironment, chemoresistance, angiogenesis
Current Drug Targets
Title: Targeting the Leukemia Microenvironment
Volume: 8 Issue: 6
Author(s): Marina Konopleva and Michael Andreeff
Affiliation:
Keywords: Leukemia, microenvironment, chemoresistance, angiogenesis
Abstract: Normal hematopoiesis is maintained by dynamic interactions between hematopoietic cells and the bone marrow microenvironment. In hematological malignancies, there are reciprocal interactions between leukemic cells and cells of the bone marrow microenvironment such as stroma, osteoblasts and endothelium. In this review, we will discuss the influence of the microenvironment on the evolution of the leukemic phenotype. We propose that specific niches within the bone marrow microenvironment may provide a sanctuary for subpopulations of leukemic cells to evade chemotherapyinduced death and allow acquisition of a drug-resistant phenotype. We will also discuss recent studies that suggest novel therapeutic interventions targeting the microenvironment/leukemia interaction. Focus on this stroma-leukemia crosstalk may result in the development of strategies that alleviate the acquisition of a chemoresistant phenotype and enhance the efficacy of therapies in hematological malignancies.
Export Options
About this article
Cite this article as:
Konopleva Marina and Andreeff Michael, Targeting the Leukemia Microenvironment, Current Drug Targets 2007; 8 (6) . https://dx.doi.org/10.2174/138945007780830827
DOI https://dx.doi.org/10.2174/138945007780830827 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Transcription Factor Binding to DNA by Competing with DNA Binders as an Approach for Controlling Gene Expression
Current Topics in Medicinal Chemistry Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review
Current Pharmaceutical Design Altered Expression of MicroRNAs in the Bone Marrow of Multiple Myeloma Patients and their Relationship to Cytogenetic Aberrations
Current Pharmaceutical Biotechnology Proteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors
Current Topics in Medicinal Chemistry Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers
Current Signal Transduction Therapy Use of Peripheral Blood Stem Cells in Tissue Engineering
Current Tissue Engineering (Discontinued) Immunotherapy for Myeloproliferative Neoplasms (MPN)
Current Cancer Drug Targets Novel and Emerging Drugs for Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Targeting Cell Death and Survival Receptors in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Rituximab Therapy and Autoimmune Disease
Current Immunology Reviews (Discontinued) Risk of Drug Resistance and Repeated Infection with <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> in Intensive Care Unit Cancer Patients
Combinatorial Chemistry & High Throughput Screening Circulating Levels of Soluble Angiogenic Factors in Multiple Myeloma: Correlation with Parameters of Disease Activity and Prognosis
Current Angiogenesis (Discontinued) Neurokinin Receptors as Potential Targets in Breast Cancer Treatment
Current Drug Discovery Technologies Current Status and Perspectives in Ceramide-Targeting Molecular Medicine
Current Pharmaceutical Design Targeting MDM2 and MDMX in Retinoblastoma
Current Cancer Drug Targets Emerging Immunosuppressive Drugs in Kidney Transplantation
Current Clinical Pharmacology Adenovirus-based Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Pre-B Cell Colony Enhancing Factor/NAMPT/Visfatin in Inflammation and Obesity- Related Disorders
Current Pharmaceutical Design Epigenetic Targets and their Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Benzimidazole Derivatives as Kinase Inhibitors
Current Medicinal Chemistry